Compare Hyatt Hotels Corporation (H) vs Moderna, Inc. (MRNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hyatt Hotels Corporation vs Moderna, Inc. — how do they compare? Hyatt Hotels Corporation trades at $179 (market cap $16.27B), while Moderna, Inc. trades at $63.66 (market cap $24.18B). The key difference: Moderna, Inc. is the larger of the two by market cap, and Hyatt Hotels Corporation pays a 0.35% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals.
| H | MRNA | |
|---|---|---|
Market Cap | $16.27B | $24.18B |
Sector | Consumer Cyclical | Health |
52-Week High | $202.09 | $81.80 |
52-Week Low | $135.42 | $22.36 |
Enterprise Value | $20.17B | $20.33B |
Dividend Yield | 0.35% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hyatt Hotels Corp (H) trades at $178.25, up 4.8% over 24 hours, near its 52-week high of $206.86. The stock shows a bearish technical signal despite recent earnings beats, with Q2 2026 EPS of $1.12 surpassing the $0.913 estimate. Fundamentals reveal a high P/E ratio of 213.14 and thin net income margin of 1.1%, though revenue grew to $7.10B in 2025. Analyst consensus is a 'Hold' with a $199.55 price target, while recent news highlights valuation concerns amid fee growth and RevPAR gains.
Outlook is mixed: strong fee growth and a record pipeline support expansion, but high valuation, project delays, and debt pose risks. The stock offers potential from operational momentum, yet investors face headwinds from regional weakness and rich multiples. Net cash flow turned negative in 2025, underscoring financial pressure despite EBITDA growth.
Moderna (MRNA) trades at $63.70, up 6.5% recently, with a bullish technical signal and strong moving average support. Despite negative net income margins, the company beat Q2 2026 EPS estimates and secured FDA approval for its mRNA flu vaccine, mFLUSIVA, signaling diversification beyond COVID-19. Revenue has declined from pandemic peaks but is projected to stabilize around $2.2B in 2026.
The outlook is mixed: near-term catalysts from new vaccine approvals and pipeline progress offer upside, but persistent losses and high valuation multiples pose risks. Analyst consensus is cautious with a hold-heavy rating, reflecting uncertainty over profitability timelines amid ongoing R&D investments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Hyatt Hotels Corporation
Hyatt is an operator of 1,162 owned (5% of total rooms) and managed and franchise (95%) properties across roughly 20 upscale luxury brands, which includes vacation brands (Apple Leisure Group, Hyatt Ziva and Hyatt Zilara), the recently launched full-service lifestyle brand Hyatt Centric, the soft lifestyle brand Unbound, and the wellness brand Miraval. Hyatt acquired Two Roads in November 2018 and Apple Leisure Group in 2021. The regional exposure as a percentage of total rooms is 66% Americas, 18% Asia-Pacific, and 16% rest of world.
Read more on H →About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →
